The number of opioids encapsulated by the US FDA's risk evaluation and mitigation strategy (REMS) has now increased nearly six-fold, as the agency officially extended it to immediate-release (IR) opioids intended for use in an outpatient setting.
When first created in 2012, the REMS only applied to 62 extended-release (ER) and long-acting (LA) products, but the extension...